Table 1

Patient characteristics at baseline and 5-year follow-up

Baseline5-year follow-upp Value baseline vs 5-year follow-up
CharacteristicFemaleMalep Value for comparison of results in women and menFemaleMalep Value for comparison of results in women and menFemaleMale
TJC 686.3 (8.8)4.6 (6.3)p=0.134.6 (7.6)2.3 (4.6)p=0.0170.0720.003
SJC 664.7 (5.2)3.9 (4.6)p=0.271.4 (2.1)1.7 (3.8)p=0.45<0.001<0.001
ESR22.9 (22.1)13.7 (16.8)p=0.00214.7 (14.2)8.7 (8.8)p=0.001<0.0010.012
CRP20.7 (32.6)12.2 (11.8)p=0.0278.2 (10.7)6.3 (5.0)p=0.12<0.001<0.001
DAS283.69 (1.34)3.03 (1.21)p=0.0012.88 (1.13)2.11 (1.23)p<0.001<0.001<0.001
ΔDAS28−0.789 (1.43)−0.951 (1.42)p=0.46
DAPSA22.83 (15.99)16.45 (12.38)p=0.00413.66 (10.94)10.2 (10.79)p=0.036<0.001<0.001
ΔDAPSA−8.73 (16.44)−6.93p=0.46
MDA/REM9 (8%)/ 2 (1.8%)13 (15.9%)/ 1 (1.2%)p=0.086/ p=1.035 (32.7%)/ 21 (25.3%)40 (50%)/ 21 25.3%)p=0.017/ p=0.021<0.001/ 0.003<0.001/ <0.001
HAQ0.77 (0.56)0.48 (0.41)p<0.0010.66 (0.66)0.33 (0.51)p<0.0010.090.08
Any dactylitis33 (29%)28 (34%)p=0.469 (10%)12 (15%)p=0.16<0.0010.004
VAS global46.3 (25.5)38.6 (23.7)p=0.03734.3 (23.4)28.4 (25.2)p=0.098<0.001<0.001
VAS pain48.4 (25.4)38.3 (23.7)p=0.00632.7 (25.0)28.5 (24.6)p=0.249<0.001<0.001
Psoriasis skin/nails/PPP86 (76.1%)/ 37 (33.3%)/ 19 (16.8%)72 (88.9%)/ 25 (30.9%)/ 4 (4.9%)p=0.024/ 0.28/ 0.01274 (66.7%)/ 26 (23.4%)/ 8 (7.2%)66 (80.5%)/ 30 (36.6%)/ 1 (1.2%)p=0.033/ 0.046/ 0.0810.095/ 0.705/ 0.0010.09/ 0.275/ 0.18
PASI2.88 (3.42)3.42 (4.08)p=0.3252.03 (3.02)2.64 (2.90)p=0.1710.0030.052
  • CRP, C-reactive protein (mg/dl); DAPSA, Disease Activity Index for Psoriatic Arthritis; DAS28, Disease Activity Score including 28 joints; ESR, erythrocyte sedimentation rate (mm/first hour); HAQ, Health Assessment Questionnaire; MDA, minimal disease activity; PASI, psoriasis area and severity index; PPP, pustulosis palmoplantaris; REM, remission; SJC, swollen joint count; TJC, tender joint count; VAS, visual analogue scale.